Results 1 to 10 of about 482,975 (382)
Anticoagulants and Osteoporosis [PDF]
International Journal of Molecular Sciences, 2019 Anticoagulant agents are widely used in the treatment of thromboembolic events and in stroke prevention. Data about their effects on bone tissue are in some cases limited or inconsistent (oral anti-vitamin K agents), and in others are sufficiently strong (heparins) to suggest caution in their use in subjects at risk of osteoporosis.
Signorelli S. S. +5 more
openaire +2 more sources
Are Three Weeks of Oral Anticoagulation Sufficient for Safe Cardioversion in Atrial Fibrillation?
Medicina, 2021 Background and Objectives: Patients with atrial fibrillation (AF), lasting >48 h, considered for cardioversion, are recommended ≥3 weeks of oral anticoagulation before sinus rhythm restoration because of high risk of development of left atrial thrombosis
Stefan Naydenov +2 more
doaj +1 more source
Frontiers in Medicine, 2021 Background: Patients with splenic infarction (SI) are associated with a prothrombotic state and are vulnerable to subsequent thromboembolic complications. However, due to its rarity, there is no established treatment modality in this population. We aimed
Chieh-Ching Yen +13 more
doaj +1 more source
Verification of selective and individual pulmonary thromboembolism prophylaxes for cesarean delivery [PDF]
Obstetrics & Gynecology Science, 2023 Objective This study aimed to verify the utility of simple, safe, and effective venous thromboembolism (VTE) prophylaxis and implement it with few adverse events during cesarean delivery.
Ryuji Kawaguchi +5 more
doaj +1 more source
British Medical Bulletin, 2000 Anticoagulation is a treatment with significant and life threatening complications requiring that the balance of risk and benefit be individually assessed in each patient. The risks are greater in the elderly and those with hypertension, falls and gastrointestinal disease.
openaire +2 more sources
Atrial fibrillation in elderly patients. Features of using rivaroxaban
Атеротромбоз, 2020 The problem of anticoagulant treatment of elderly patients with atrial fibrillation (AF) is very topical for everyday medical practice because, on the one hand, the proportion of elderly patients among those who have AF is constantly increasing, and, on ...
A. D. Erlikh
doaj +1 more source
Journal of Pharmacy and Pharmacology, 1949 Abstract The processes that underly the clotting of blood are still far from adequately understood, in spite of the many facts uncovered by generations of patient investigators. The classical scheme associated with the name of Morawitz1, although neither complete nor universally accepted, is still useful as a summary of the main events ...
openaire +2 more sources
DABIGATRAN ETEXILATE IN ELDERL Y PATIENTS WITH ATRIAL FIBRILLATION: WHATS NEW?
Евразийский Кардиологический Журнал, 2017 The article discusses stroke prevention in elderly patients with atrial fibrillation. The principles of choosing anticoagulant therapy in this group of patients are discussed.
O. N. Tkacheva, N. M. Vorobyeva
doaj +1 more source
Experimental antithrombotic effect of medicinal plants: A critical review
Indian Journal of Ayurveda and Integrative Medicine KLEU, 2022 Thrombosis is one of the major causes of morbidity and mortality in a wide range of cardiovascular disorders (CVDs). CVDs are listed among top ten killer diseases. Antithrombotic drugs reduce the incidence of cardiovascular events about 20%–25% in people.
Shweta Mandloi +2 more
doaj +1 more source
Lung India, 2021 Hemostatic derangement is a hallmark in severe COVID-19. Markedly elevation of D-dimer and fibrinogen degradation product levels were observed in patients with severe COVID-19 higher and 71.4% of nonsurvivors met the International Society of Thrombosis ...
Ka U Lio, Parth Rali
doaj +1 more source